Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carbamazepine
Drug ID BADD_D00356
Description Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.[L1335] Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.[A180319]
Indications and Usage Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
Marketing Status approved; investigational
ATC Code N03AF01
DrugBank ID DB00564
KEGG ID D00252
MeSH ID D002220
PubChem ID 2554
TTD Drug ID D04MSM
NDC Product Code 62512-0024; 30698-421; 50268-172; 60687-583; 63629-9292; 66993-409; 70518-3266; 70771-1470; 0615-8125; 0781-5987; 0904-6885; 49452-1705; 63552-060; 0078-0510; 0078-0511; 16571-681; 16714-064; 0093-0778; 17856-0029; 29033-019; 30698-419; 35561-355; 50090-0384; 51672-4047; 51672-4151; 54092-173; 60429-934; 60687-594; 63629-8721; 70518-0181; 70771-1469; 70954-240; 71205-025; 75834-220; 12658-0525; 12658-0526; 0904-7116; 42419-014; 35561-357; 51672-4149; 54092-171; 59746-789; 60505-2805; 63629-8743; 66993-407; 67386-621; 68788-7210; 70518-1433; 59746-790; 63629-8753; 68084-562; 68382-557; 70518-3176; 0781-5988; 16714-063; 27241-233; 29033-004; 29300-382; 35561-356; 51407-215; 60505-2807; 70518-1545; 71930-073; 72162-2021; 0781-8016; 0832-6022; 12658-0561; 12658-0565; 48087-0051; 70966-0020; 76003-0251; 13668-268; 0093-0109; 27241-232; 43063-328; 50268-170; 54092-172; 60505-2806; 68788-7825; 70518-1436; 70518-2242; 70518-3335; 71335-0461; 71335-0691; 71930-072; 75834-221; 0904-3854; 51927-2176; 13668-271; 51672-4125; 63629-8715; 68084-444; 68382-555; 70518-1769; 70518-2456; 70518-3699; 70518-3773; 0832-6023; 12658-0452; 51552-0653; 62991-1027; 65344-0028; 65344-0040; 0078-0512; 27241-231; 0121-0947; 43353-953; 59746-791; 70518-2426; 70518-3146; 71930-074; 72189-157; 0904-6172; 12658-0406; 12658-0541; 0078-0509; 0093-0090; 29033-020; 51672-4005; 51672-4123; 55154-1396; 60505-0183; 60687-479; 63629-8720; 68094-007; 68382-556; 70518-2841; 70518-3591; 70518-3694; 71335-1730; 12658-0486; 38779-0114; 48087-0052; 0078-0508; 16714-065; 30698-423; 50268-171; 51672-4150; 58118-0268; 66993-408; 68071-2701; 70518-2489; 70518-3174; 70771-1468; 0615-3505; 72664-218; 0832-6024; 65372-1102; 16571-680; 16571-682; 0121-1894; 50090-5740; 51672-4041; 51672-4124; 60429-032
UNII 33CM23913M
Synonyms Carbamazepine | Carbamazepine Acetate | Carbamazepine Dihydrate | Carbamazepine Hydrochloride | Carbamazepine L-Tartrate (4:1) | Carbamazepine Anhydrous | Carbamazepine Sulfate (2:1) | Carbazepin | Epitol | Finlepsin | Neurotol | Tegretol | Amizepine | Carbamazepine Phosphate
Chemical Information
Molecular Formula C15H12N2O
CAS Registry Number 298-46-4
SMILES C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal oedema07.11.01.0120.000186%Not Available
Multi-organ disorder08.01.03.0740.000279%Not Available
Poor sucking reflex18.04.04.011; 17.02.01.0080.000372%Not Available
Sopor19.02.04.002; 17.02.04.0210.004928%Not Available
Psychogenic seizure17.12.03.042; 19.24.01.0070.000186%Not Available
Communication disorder19.19.01.0080.000279%Not Available
Pyelocaliectasis20.01.06.0110.000186%Not Available
Foaming at mouth17.02.05.056; 08.01.03.070; 07.05.05.0190.000372%Not Available
Eosinophilic oesophagitis10.01.01.030; 07.08.05.006; 01.02.04.0160.000186%Not Available
Tachyphrenia19.10.03.010; 17.03.03.0070.000725%Not Available
Excessive eye blinking17.17.02.010; 06.05.01.0040.000279%Not Available
Mucosal hyperaemia08.01.06.0220.000279%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000651%Not Available
Oral mucosal erythema07.05.05.0230.000372%Not Available
Delivery18.08.02.0060.000186%Not Available
Skin plaque23.03.03.0440.000744%Not Available
Overlap syndrome23.03.02.018; 15.06.01.016; 10.04.04.0160.000744%Not Available
Frontotemporal dementia17.03.01.007; 19.20.02.0080.000279%Not Available
Motor developmental delay19.22.01.005; 17.01.02.0230.000744%Not Available
Seizure cluster17.12.03.0290.000186%Not Available
Hyporesponsive to stimuli17.02.05.0570.000186%Not Available
Encephalitis autoimmune17.06.05.002; 16.32.01.006; 10.04.10.0120.000186%Not Available
Fulminant type 1 diabetes mellitus10.04.08.013; 14.06.01.013; 05.06.01.0130.000279%Not Available
Decerebrate posture15.03.05.008; 17.02.05.0540.000186%Not Available
Hypoosmolar state14.05.01.0100.000186%Not Available
Haemorrhagic necrotic pancreatitis24.07.02.047; 07.18.01.0100.000186%Not Available
Infantile apnoea22.11.02.004; 18.04.15.0030.000186%Not Available
Neuromyelitis optica spectrum disorder17.16.02.005; 10.04.10.015; 06.04.08.0030.000186%Not Available
Selective eating disorder19.09.01.012; 14.03.02.0240.000186%Not Available
Administration site pain12.07.04.029; 08.02.04.0290.000186%Not Available
The 30th Page    First    Pre   30 31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene